Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial

Anti-PD-1 monoclonal antibody is approved as an option for third-line treatment of advanced gastric and gastroesophageal junction (G/GEJ) cancer in several countries, but no anti-PD-1 monoclonal antibody treatment is yet approved for first-line treatment of advanced G/GEJ cancer. We report a phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianming, Xu, Nong, Bai, Yuxian, Liu, Rongrui, Mao, Chenyu, Sui, Hong, Wang, Xiaofei, Jiang, Qian, Dou, Yiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781732/
https://www.ncbi.nlm.nih.gov/pubmed/33457083
http://dx.doi.org/10.1080/2162402X.2020.1864908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781732/
https://www.ncbi.nlm.nih.gov/pubmed/33457083
http://dx.doi.org/10.1080/2162402X.2020.1864908

Ejemplares similares